Literature DB >> 33409784

The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.

Sang Ik Park1, Chong Hyun Suh2, Jeffrey P Guenette3, Raymond Y Huang3, Ho Sung Kim1.   

Abstract

OBJECTIVES: To evaluate the diagnostic performance of the T2-FLAIR mismatch sign for prediction of isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted lower-grade gliomas (LGGs) and review studies with false positive results.
METHODS: The MEDLINE and EMBASE databases were searched up to March 13, 2020, to identify articles reporting the diagnostic performance of the T2-FLAIR mismatch sign for prediction of IDH-mutant, 1p/19q-noncodeleted LGGs (IDHmut-Noncodel) using the search terms (T2 FLAIR mismatch). Pooled sensitivity, specificity, and correlation coefficient for interobserver agreement were calculated.
RESULTS: Twelve studies including a total of 1053 patients were included. The median age was 43 (median; range, 14-56). The pooled sensitivity and specificity were 42% (95% CI, 28-58%) and 100% (95% CI, 88-100%), respectively. According to the HSROC curve, the area under the curve was 0.77 (95% CI, 0.73-0.80). Considerable heterogeneity was possible among the studies in terms of both sensitivity and specificity. A threshold effect was suggested and was considered to explain most of the heterogeneity. Four studies reported false positive results for the T2-FLAIR mismatch sign, including dysembryoplastic neuroepithelial tumor, pediatric-type gliomas, and non-neoplastic lesions. The 2 original articles with false positive results showed the highest sensitivities among the 10 studies included in the quantitative analysis, supporting the probability of the threshold effect. The pooled correlation coefficient was 0.87 (95% CI, 0.73-0.94).
CONCLUSIONS: The T2-FLAIR mismatch sign had a high specificity and interobserver agreement for the prediction of IDHmut-Noncodel. However, the sign demonstrated low sensitivity, and a few studies with false positive cases were also reported. KEY POINTS: • The pooled sensitivity and specificity of the T2-FLAIR mismatch sign for prediction of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas were 42% and 100%, respectively. • Four studies reported false positive results. • The pooled correlation coefficient was 0.87, suggesting almost perfect interobserver agreement.

Entities:  

Keywords:  Astrocytoma; Brain neoplasms; Glioma; Magnetic resonance imaging; Oligodendroglioma

Year:  2021        PMID: 33409784     DOI: 10.1007/s00330-020-07467-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  2 in total

1.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

2.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

  2 in total
  3 in total

1.  Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.

Authors:  Arian Lasocki; Michael E Buckland; Katharine J Drummond; Heng Wei; Jing Xie; Michael Christie; Andrew Neal; Frank Gaillard
Journal:  Neuroradiology       Date:  2022-05-24       Impact factor: 2.804

2.  T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.

Authors:  Shinji Yamashita; Hideo Takeshima; Yoshihito Kadota; Minako Azuma; Tsuyoshi Fukushima; Natsuki Ogasawara; Tomoki Kawano; Mitsuru Tamura; Jyunichiro Muta; Kiyotaka Saito; Go Takeishi; Asako Mizuguchi; Takashi Watanabe; Hajime Ohta; Kiyotaka Yokogami
Journal:  Brain Tumor Pathol       Date:  2022-04-28       Impact factor: 3.298

Review 3.  Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.

Authors:  Saivenkat Vagvala; Jeffrey P Guenette; Camilo Jaimes; Raymond Y Huang
Journal:  Cancer Imaging       Date:  2022-04-18       Impact factor: 5.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.